Hennessy Capital Acquisition Corporation IV (NASDAQ:HCAC) announced it has completed its combination with EV company Canoo after securing shareholder approval earlier today.
The parties did not share redemption figures in the announcement, but it is unlikely they were significant as Hennessy opened at $19.20 this morning ahead of the vote.
The combined entity’s shares and warrants will trade on the Nasdaq under the ticker symbols “GOEV” and “GOEVW,” respectively, beginning tomorrow, December 22.
Hennessy initially announced its $1.8 billion combination with Canoo on September 18. Canoo has developed a skateboard-style battery and drivetrain and plans to offer both branded vehicles on a subscription basis and co-develop designs with carmakers Hyundai and Kia.
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...